Home Ingredients Bacillus licheniformis (Standalone Probiotic)
Gut Health

Bacillus licheniformis (Standalone Probiotic)

Bacillus licheniformis — strains CMCC63516 (Zhengchangsheng), SL-307
Evidence Level
Moderate
3 Clinical Trials
7 Documented Benefits
3/5 Evidence Score

Spore-forming Bacillus probiotic with bacitracin antibiotic production. Key strains: CMCC63516 (Zhengchangsheng, NorthEast Pharm — Chinese clinical use); SL-307 (component of multi-strain spore probiotic blends). Spore form is heat/acid/bile resistant — survives stomach acid and reaches the small intestine without enteric coating. Studied for pediatric antibiotic-associated diarrhea prevention, with the finding that baseline gut microbiome structure affects how much protection the probiotic provides. Also studied as an adjunct to vancomycin to help preserve gut microbiota, with a broader evidence base for microbiota modulation and GI applications.

Studied Dose B. licheniformis CMCC63516 ~2-5×10⁸ CFU/day.
Active Compound Bacillus licheniformis spores (strains CMCC63516/Zhengchangsheng, SL-307); Gram-positive spore-forming bacterium.

Benefits

Pediatric AAD prevention RCT

First multi-center double-blind RCT in Chinese pediatric antibiotic-associated diarrhea. Baseline gut microbiome structure affects how much the probiotic protects — an important biomarker stratification finding, with P. copri, B. coprocola, and B. plebeius showing positive correlations. Limitations: small sample size and non-uniform antibiotics across centers.

Supported by Trial 1

CDI gut microbiota preservation

Given for 5 days alongside vancomycin in C. difficile infection patients, B. licheniformis preserved gut microbiota during classical CDI antibiotic treatment. Relevant in severe antibiotic-associated diarrhea where standard CDI therapy disrupts microbiota.

Supported by Trial 2

Sporulation pharmaceutical advantage

Spore form provides heat, acid, and bile resistance — survives gastric transit without enteric coating, room-temperature stable for shelf life. Practical pharmaceutical advantage over typical Lactobacillus/Bifidobacterium probiotics that require refrigeration and enteric protection.

Supported by Trial 1

Microbiota modulation (systematic review)

A systematic review of 68 articles found the most-addressed area was the gastrointestinal system (microbiota modulation, gut benefits, treatment of enteritis/colitis/diarrhea). Comprehensive evidence base supporting GI applications.

Supported by Trial 3

Bacitracin antibiotic production

B. licheniformis produces bacitracin — a polypeptide antibiotic active against gram-positive bacteria. Distinguishing antimicrobial mechanism among Bacillus species; supports the competitive exclusion of pathogenic gram-positive bacteria during dysbiosis.

Supported by Trial 2, Trial 1

Component of multi-strain spore probiotic blends

B. licheniformis SL-307 is one of several Bacillus strains used in multi-strain spore-based probiotic blends marketed for gut health and microbiome support. Blends typically combine 4-5 spore-forming Bacillus species for complementary mechanisms (carotenoid production, antimicrobial peptides, microbiome reconditioning). Strain-specific evidence for SL-307 outside such blends is limited — most B. licheniformis evidence is on CMCC63516 (Zhengchangsheng®).

Supported by Trial 1

Spore germination and colonization

Spores germinate in the small intestine, transitioning to vegetative cells that produce the bacitracin and metabolite signals. Transient colonization (typical of Bacillus probiotics — they don't permanently establish in the gut) but produces sustained metabolite effects during transit.

Supported by Trial 1

Mechanism of action

1

Spore-form delivery (heat/acid/bile resistance)

Endospore form survives gastric acid, bile, and heat exposure — reaches the small intestine intact without enteric coating. Room-temperature stable for shelf life. Distinguishing pharmaceutical advantage.

2

Bacitracin antibiotic production

B. licheniformis produces bacitracin (polypeptide antibiotic active against gram-positive bacteria). Distinguishing antimicrobial activity among Bacillus probiotics.

3

Microbiota modulation during dysbiosis

Competitive exclusion of pathogens combined with commensal support during antibiotic-induced or CDI-related dysbiosis. Mechanism for the AAD prevention and CDI adjunct applications.

4

Spore germination + vegetative metabolite production

Spores germinate in the small intestine to vegetative cells producing bacitracin and other metabolites. Transient colonization with sustained metabolite signals during transit.

5

Anti-inflammatory effects

Anti-inflammatory effects contribute to the broader GI applications beyond pure microbiota modulation.

6

Baseline microbiome interaction (Zhou 2023 finding)

Pre-existing baseline microbiome composition impacts response variability. Positive correlations with P. copri, B. coprocola, and B. plebeius may indicate biomarker stratification for clinical translation.

Clinical trials

1
B. licheniformis CMCC63516 Pediatric AAD Multi-Center Clinical Trial

Clinical evidence on Bacillus licheniformis (Standalone Probiotic) for the indications and outcomes described.

Clinical population described in trial publication.

Zhou Q et al. 2023 (Clin Transl Med, doi:10.1002/ctm2.1184, ChiCTR-IPR-16009033). First multi-center double-blind clinical trial in Chinese pediatric AAD. Multi-hospital sites. Baseline gut microbiome structure impacts probiotic protection — biomarker stratification finding. P. copri, B. coprocola, B. plebeius positive correlations. Limitations: small sample, non-uniform antibiotics.

2
CDI Gut Microbiota Preservation 5-Day Adjunct

5-day B. licheniformis adjunct to vancomycin in CDI patients.

Clinical population described in trial publication.

5-day B. licheniformis adjunct to vancomycin in CDI patients. Preserved gut microbiota during classical CDI antibiotic treatment.

3
Front Evidence Review

(Front) — evidence review of 68 articles.

Clinical population described in trial publication.

(Front) — evidence review of 68 articles. Most addressed area: gastrointestinal system (microbiota modulation, gut benefits, enteritis/colitis/diarrhea treatment). Comprehensive evidence base for GI applications.

Side effects and drug interactions

Common Potential side effects

Generally well-tolerated; spore-forming probiotic with extensive Chinese clinical use record (Zhengchangsheng).
Mild GI upset, bloating (rare; transient).
Pregnancy/lactation: limited specific data; consult physician.
Long-term safety: extensive commercial use record (NorthEast Pharm Zhengchangsheng).
Allergic reactions (rare).
Severely immunocompromised individuals: caution (applies to all probiotics).
Bacitracin allergies: theoretical caution (B. licheniformis produces bacitracin).

Important Drug interactions

Antibiotics: compatible with most antibiotics — spore-forming probiotic survives concurrent antibiotic exposure better than typical Lactobacillus/Bifidobacterium.
Vancomycin: compatible per PMC11858508 5-day CDI adjunct evidence.
Most medications: well-tolerated combination profile.
Immunosuppressants: caution (applies to all probiotics).
Other probiotics: compatible (often multi-strain formulations).
Anticoagulants: no interactions documented.

More Gut Health Ingredients

Gut Health
Pancrelipase / Pancreatin
Pancrelipase (also called pancreatin) is a standardized blend of three primary pancreatic…
Gut Health
Sunfiber® (Partially Hydrolyzed Guar Gum)
Sunfiber® is the original and most extensively clinically-studied partially hydrolyzed gua…
Gut Health
Peppermint (Mentha × piperita)
Peppermint is a hybrid mint (Mentha aquatica × Mentha spicata) whose leaves and extracted…
Gut Health
PepZinGI® (Zinc-Carnosine for Gut Lining)
PepZinGI® (NutriScience Innovations) is a unique chelate of zinc and L-carnosine in a 1:1…

Explore Other Ingredients

Immune Support
Probiotics (Multi-strain Blends)
Multi-strain probiotic blends are the most common form of probiotic supplements — typicall…
Muscle & Recovery
L-Glutamine
L-glutamine is the most abundant amino acid in the body and the primary metabolic fuel for…
Metabolic Health
Inulin
Inulin is a soluble prebiotic fiber found naturally in chicory root, agave, and many veget…

Frequently asked questions about Bacillus licheniformis (Standalone Probiotic)

What is Bacillus licheniformis used for?

B. licheniformis is a spore-forming probiotic studied for digestive balance and for supporting recovery of healthy gut flora, including during and after antibiotics. Its spores make it stable and acid-resistant.

How much B. licheniformis should I take?

It is dosed in the billions of CFU per day, often in combination products; follow the specific product's labeling. As a spore former, it is shelf-stable and survives stomach acid well.

Can B. licheniformis help during antibiotics?

It is studied for supporting gut flora during antibiotic use; some spore formers can be taken alongside antibiotics, but follow product guidance and your doctor's advice on timing.

Is B. licheniformis safe?

It is generally well tolerated in healthy people. As with all live probiotics, severely immunocompromised or critically ill people should consult a doctor first.

What is Bacillus licheniformis?

Spore-forming Bacillus probiotic with bacitracin antibiotic production. Key strains: CMCC63516 (Zhengchangsheng, NorthEast Pharm — Chinese clinical use); SL-307 (component of multi-strain spore probiotic blends).

What is the recommended dosage of Bacillus licheniformis?

The clinically studied dose is B. licheniformis CMCC63516 ~2-5×10⁸ CFU/day. Always follow the product label and check with a healthcare provider for personal advice.

Is Bacillus licheniformis safe, and does it have side effects?

For most healthy adults, Bacillus licheniformis is well tolerated at studied doses. Reported effects can include: Generally well-tolerated; spore-forming probiotic with extensive Chinese clinical use record (Zhengchangsheng). Mild GI upset, bloating (rare; transient). It may also interact with some medications. Bacillus licheniformis is not right for everyone, so check with a healthcare provider first if you are pregnant or breastfeeding, have a medical condition, or take prescription medication.

Does Bacillus licheniformis interact with any medications?

Possible interactions include: Antibiotics: compatible with most antibiotics — spore-forming probiotic survives concurrent antibiotic exposure better than typical Lactobacillus/Bifidobacterium. Vancomycin: compatible per PMC11858508 5-day CDI adjunct evidence. If you take prescription medication, check with a pharmacist or doctor before using it.

How strong is the scientific evidence for Bacillus licheniformis?

NutraSmarts rates the evidence for Bacillus licheniformis as Moderate (3 out of 5). It is backed by 3 clinical trials and 1 cited reference summarized on this page. A higher rating reflects more, larger, and better-designed human studies.

References(1 citations)

Evidence ratings on NutraSmarts are based on the totality of human clinical research, with emphasis on randomized controlled trials, meta-analyses, and systematic reviews. The references below directly support claims made throughout this page.

  1. Zhou Q, Dai W, Bao Y, et al. Baseline gut microbiome impacts probiotics Bacillus licheniformis CMCC63516 in modulating the gut microbiome and preventing antibiotic-associated diarrhea: A double-blind, randomized controlled trial. Clin Transl Med. 2023;13(4):e1184..PubMedUsed to support: Randomized trial of Bacillus licheniformis preventing antibiotic-associated diarrhea.